Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22490880 | 0.80 | TNF (0.37) | PDE4DKCNA3HPGDLMNA | |
| SCHEMBL23488282 | 0.79 | LGALS8 (0.40) | SLC6A2PDE4DKCNA3SLC5A2SLC5A1 | |
| SCHEMBL23488579 | 0.79 | LGALS8 (0.40) | SLC6A2PDE4DKCNA3SLC5A2SLC5A1 | |
| SCHEMBL23488516 | 0.79 | LGALS8 (0.40) | SLC6A2PDE4DKCNA3SLC5A2SLC5A1 | |
| SCHEMBL23488157 | 0.76 | LGALS8 (0.44) | SLC6A2PDE4DKCNA3SLC5A2SLC5A1 | |
| SCHEMBL22490898 | 0.75 | PDE4D (0.45) | PDE4DKCNA3PTPN1HPGDNPC1 | |
| SCHEMBL22490875 | 0.74 | PARP10 (0.49) | SLC6A2NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL22490933 | 0.74 | PARP10 (0.49) | SLC6A2NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL22490915 | 0.74 | PARP10 (0.49) | SLC6A2NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL23488171 | 0.74 | LGALS8 (0.47) | SLC6A2SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
| EP-3717463-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | Sanofi (FR) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | SLC6A2 1655/4885PDE4D 1147/4885KCNA3 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.